Vertex Pharmaceuticals (VRTX) total liabilities

Total liabilities · fiscal 2025
$6.98B

Vertex Pharmaceuticals (VRTX) had total liabilities of $6.98B at the end of fiscal 2025 (December 31, 2025). That is 13.9% higher than the $6.12B of fiscal 2024. Figures as of 18 Nov 2026, 19:48 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$6.98B
Change on fiscal 2024
+13.9%
Growth, 5 years
+17.9% a year
Growth, 10 years
+17.4% a year
Highest on record
$6.98Bfiscal 2025
Lowest on record
$859.14Mfiscal 2009
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Vertex Pharmaceuticals total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 17.9% a year; over ten years the rate was 17.4% a year. Across the 17 fiscal years on record (2009–2025), the highest was $6.98B in fiscal 2025 and the lowest $859.14M in fiscal 2009.

History · 17 fiscal years

Total liabilities by fiscal year

Vertex Pharmaceuticals total liabilities, year by year

Vertex Pharmaceuticals (VRTX) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$6.98B 13.9% up
2024$6.12B 18.9% up
2023$5.15B 21.5% up
2022$4.24B 27.2% up
2021$3.33B 8.7% up
2020$3.07B 37.2% up
2019$2.23B 23.3% up
2018$1.81B 20.4% up
2017$1.50B 3.5% down
2016$1.56B 10.9% up
2015$1.40B 13.4% up
2014$1.24B 28.7% up
2013$962.64M 36.9% down
2012$1.52B 23.1% up
2011$1.24B 1.4% up
2010$1.22B 42.2% up
2009$859.14M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Vertex Pharmaceuticals and comparable companies
CompanyTotal liabilitiesFiscal year
Pfizer PFE$121.39B2025
Danaher DHR$30.92B2025
Intuitive Surgical ISRG$2.52B2025
Vertex Pharmaceuticals VRTX$6.98B2025
Medtronic MDT$42.96B2026
Bristol-Myers Squibb BMY$71.53B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on VRTX

Vertex Pharmaceuticals, figure by figure

Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecardAll health care companies by market value

Vertex Pharmaceuticals total liabilities: questions and answers

How large are Vertex Pharmaceuticals's total liabilities?

Vertex Pharmaceuticals (VRTX) had total liabilities of $6.98B at the end of fiscal 2025 (December 31, 2025). That is 13.9% higher than the $6.12B of fiscal 2024.

What is the growth rate of Vertex Pharmaceuticals's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 17.9% a year; over ten years the rate was 17.4% a year.

What are the highest and lowest total liabilities figures on record for Vertex Pharmaceuticals?

Across the 17 fiscal years on record (2009–2025), the highest was $6.98B in fiscal 2025 and the lowest $859.14M in fiscal 2009.

How is Vertex Pharmaceuticals's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Vertex Pharmaceuticals it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/VRTX/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.